The lidocaine, 7%/tetracaine, 7%, cream Pliaglis (Galderma Laboratories, Fort Worth, Texas) (hereinafter, “LT peel”) is a novel topical anesthetic cream that forms a self-occlusive, pliable membrane on exposure to air. The LT peel has been shown to be a safe and effective form of local anesthesia for various dermatologic procedures.1 Minimal adverse effects associated with the LT peel have been reported, limited primarily to transient skin erythema with or without skin discoloration or edema.1 Herein, we report a case of contact urticaria and discuss possible causes of such allergic manifestations and potential hazards and precautions recommended with the use of the LT peel.
Slightly edematous, well-demarcated, erythematous plaque appearing 15 minutes after application of lidocaine, 7%/tetracaine, 7%, cream to the face. Arrows designate the margins of the plaque and correspond to the edges of the area where the cream was applied.
Well-demarcated areas of facial erythema and mild lip edema without evidence of lingual edema.
Mild lip edema occurred 15 minutes after lidocaine, 7%/tetracaine, 7%, cream was applied to the face (A) and resolved, as did the contact urticaria, within 30 minutes of treatment with a single 50-mg oral dose of diphenhydramine (B).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.